Phenyl Linked Quinolinyl Modulators for RORγt Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for immune-mediated inflammatory diseases, such as psoriasis and rheumatoid arthritis, often target broader pathways like IL-12 and IL-23, with limited specificity and efficacy in inhibiting the Th17 pathway, which is driven by RORγt activity.
Innovation Solution
Development of substituted quinoline compounds that specifically modulate RORγt activity, reducing IL-17 production and targeting the Th17 pathway to treat inflammatory syndromes and disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibodies targeting IL-12 and IL-23 are used (e.g., ustekinumab), then inhibition of Th17 pathway is achieved, but specificity is limited and efficacy in fully blocking RORγt-driven inflammation is insufficient
Solution Approach 1:
The patent extracts and isolates the specific RORγt target from the broader IL-12/IL-23 pathway by designing compounds that bind directly to RORγt nuclear receptor. This extraction of the specific target (RORγt) from the general pathway (IL-12/IL-23) enables selective inhibition of Th17 cell differentiation without affecting other cytokine pathways, thereby resolving the contradiction between efficacy and specificity.
Solution Approach 2:
The patent applies local quality by creating compounds with specific molecular structures (substituted quinoline, phenyl-linked quinolinyl, indole, or indole N-oxide cores) that are optimized for binding to the specific RORγt receptor site. The localized structural features at the molecular level enable selective interaction with RORγt, providing pathway-specific inhibition while maintaining broad applicability across different inflammatory diseases driven by Th17 cells.
2Object-affected harmful factors
If broad pathway inhibition (IL-12/IL-23) is used, then Th17 pathway is suppressed, but off-target effects and limited efficacy in completely blocking RORγt activity occur
Solution Approach 1:
The patent introduces small molecule compounds as intermediaries that specifically mediate the inhibition between the therapeutic goal (blocking Th17 inflammation) and the target (RORγt receptor). These intermediary compounds act as precise messengers that transmit the inhibitory signal only to RORγt, avoiding off-target effects while effectively suppressing the harmful inflammatory response driven by Th17 cells.
Data Source
AI summary
The present invention comprises compounds of Formula I. Formula I wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.